Overview

Founded in 2008 Privately held technology development company Reorganized under new ownership as Tamarisk

Technologies Group in 2014

About Us

Cost effectively increasing the oral bioavailability of existing and emerging drug technologies through better drug delivery design.

Tamarisk’s Value Statement to the Pharmaceutical Industry

Our drug carrier platform utilizes an alginate particle substrate engineered to provide targeted GI delivery. Additional on-board attributes can be added to provide subtle manipulation of targeted local environmental parameters to specifically preserve payload drug activity and energize absorption pathways for increased bioavailability.

MxBATM Delivery SystemTamarisk’s Technology

Oral ingestion is generally viewed by most clinicians as the ideal delivery method and lowers the barriers for patient compliance.

Tamarisk Technologies Group has developed a patent pending oral delivery system that microencapsulates therapeutic agents within a protective substrate that can also contain customizable absorption enhancement agents, such as hydrophobic/hydrophilic stabilizers, receptor ligands, permeation enhancers, excipients, or particle enhancements, such as to optimize particle size and/or solid dispersion.

MxBATM Delivery SystemEnhanced Oral Delivery

Resistant to gastric disintegration Targeted release of the therapeutic payload within the GI

tract Capitalizes on multiple features of the local GI

environment for assisted entry into the bloodstream Provides increased bioavailability of therapeutic payload Reduced GI induced drug degradation Concentrates actives at desired point of absorption Balances the physiochemical properties of the delivery

platform to support optimal transport across the epithelia

MxBATM Delivery SystemBenefits

MxBATM Delivery SystemTamarisk’s Particle

Therapeutic agents successfully encapsulated include:

Ceftriaxone Sodium (Rocephrin) - showed 73% bioavailability in rabbits

Insulin – In vitro tests showed survival in SGF and good elution profile in SIF. Rat enterocyte cell culture tests demonstrated enhanced transport.

Resveratrol – In vivo tests in rats demonstrated significantly shorter Tmax with increased Cmax and AUC compared to controls.

* Note: A complete listing of therapeutic agents encapsulated to date is available upon request.

MxBATM Delivery SystemResults

We believe Tamarisk’s novel particle design is not only an effective solution for various therapeutics we have successfully encapsulated but is the ideal solution as a broad-spectrum platform for orally delivering the most challenging APIs in the industry.

MxBATM Delivery SystemResults

Small Molecules

Peptides

Proteins

Other Functional Molecules

Cyclic Peptides

Monoclonal antibodies

Study conducted by Charles River (Wilmington, MA) Sprague Dawley Rats Oral administration Single dose study

Mean unencapsulated Resveratrol

(20 mg/ml dose)

Tamarisk MxBA encapsulated Resveratrol

(20 mg/ml dose) ChangeAUC0-t ng*h/mL 82.8 312 3.8X increase

Cmax ng*h/mL 82.4 498 6.0X increase

tmax h 1.5 0.5 1 hr faster

MxBATM Delivery SystemResveratrol Pre-Clinical Results

Partnering Opportunity

Tamarisk's unique delivery platform is ready to be entrusted to an effective global leader in the Healthcare industry who's expertise and core values may be combined with our technology to provide the next generation of leading edge therapeutic products.

If your company is looking for the most effective oral delivery system for it's existing pharmaceutical therapies or those in it's pipeline, it's time to consider a new solution. It's time to consider Tamarisk. There's no better time than now for a technology with so much potential to make the world a better place both for us now and for generations to come.

www.tamarisktechgroup.com

Tamarisk’s MxBATM Delivery System opens new avenues of development for new drug technologies in the 21st century. Let Tamarisk custom design a delivery experience for you that is second to none.

Proof of concept test samples can be readily manufactured No additional complex synthesis High encapsulation efficiency Biologic or small molecule capable Hydrophobic or hydrophilic APIs Lab-scale operation ready to go Analytical testing and method development services available

MxBATM Delivery SystemNext Steps

Meet The Team

Dean Crowell | Executive Director

John Connell | Chairman/Director of Corp Development

A.T. Snoots, II | Director, Operations

Darrell Turner | Director, Finance

Who We Are

Tamarisk Technologies Group © 2015All Rights Reserved. No part of this presentation

may be copied, modified, printed, or presented without the author’s permission.

#NoMoreNeedles

Visit us online at

www.tamarisktechgroup.com